Vaccines for preventing pneumococcal infection in adults
about
Pneumococcal vaccine for preventing Streptococcus pneumoniae infection in HIV-infected individualsConjugated pneumococcal vaccine versus polysaccharide pneumococcal vaccine for prevention of pneumonia and invasive pneumococcal disease in immunocompetent and immunocompromised adults and childrenAdvances in the prevention, management, and treatment of community-acquired pneumoniaEfficacy of PPV23 in Preventing Pneumococcal Pneumonia in Adults at Increased Risk--A Systematic Review and Meta-AnalysisRevised adult immunization guideline recommended by the korean society of infectious diseases, 2014.Antibiotic Resistance: What are the Opportunities for Primary Care in Alleviating the Crisis?Adult vaccinationPneumococcal vaccine and patients with pulmonary diseasesA review of economic evaluations of 13-valent pneumococcal conjugate vaccine (PCV13) in adults and the elderlyPneumococcal Capsules and Their Types: Past, Present, and FuturePneumococcal Vaccination in High-Risk Individuals: Are We Doing It Right?Prevention of Community-Acquired Pneumonia with Available Pneumococcal VaccinesThe role of vaccination in preventing pneumococcal disease in adultsPneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease.Influenza and Pneumococcal Vaccination Uptake in Patients with Rheumatoid Arthritis Treated with Immunosuppressive Therapy in the UK: A Retrospective Cohort Study Using Data from the Clinical Practice Research Datalink.Do influenza and pneumococcal vaccines prevent community-acquired respiratory infections among older people with diabetes and does this vary by chronic kidney disease? A cohort study using electronic health recordsCost-effectiveness of pneumococcal vaccination strategies for the elderly in KoreaCommunity-acquired pneumonia caused by carbapenem-resistant Streptococcus pneumoniae: re-examining its prevention and treatment.Effectiveness of pneumococcal vaccines in preventing pneumonia in adults, a systematic review and meta-analyses of observational studies.Factors associated with pneumococcal vaccination among an urban elderly population in ChinaBarriers and Facilitators to Provision of Influenza and Pneumococcal Vaccines in Home Health Care AgenciesLifestyle risk factors for invasive pneumococcal disease: a systematic review.Management of community-acquired pneumonia in older adults.Pneumococcal empyema and complicated pneumonias: global trends in incidence, prevalence, and serotype epidemiology.Clinical features, etiology and outcomes of community-acquired pneumonia in patients with chronic obstructive pulmonary disease.A population-based study on the impact of hospitalization for pneumonia in different age groups.Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine when administered to healthy Japanese adults aged ≥50 years. An open-label trial.Development of Streptococcus pneumoniae Vaccines Using Live VectorsRecommendations for pneumococcal immunization outside routine childhood immunization programs in Western Europe.Differences in distribution and drug sensitivity of pathogens in lower respiratory tract infections between general wards and RICU.Pneumococcal vaccination: what have we learnt so far and what can we expect in the future?Challenges in assessing the process-outcome link in practice.Protection against Streptococcus pneumoniae lung infection after nasopharyngeal colonization requires both humoral and cellular immune responsesA randomized clinical trial of the immunogenicity of 7-valent pneumococcal conjugate vaccine compared to 23-valent polysaccharide vaccine in frail, hospitalized elderly.The burden and etiology of community-onset pneumonia in the aging Japanese population: a multicenter prospective study.The ABC of pneumococcal infections and vaccination in patients with chronic kidney disease.Cost-Effectiveness Analysis of Universal Vaccination of Adults Aged 60 Years with 23-Valent Pneumococcal Polysaccharide Vaccine versus Current Practice in Brazil.Pneumococcal polysaccharide vaccination in adults undergoing immunosuppressive treatment for inflammatory diseases--a longitudinal studySafety and tolerability of 13-valent pneumococcal conjugate vaccine in the elderly.A systematic review of the burden of vaccine preventable pneumococcal disease in UK adults.
P2860
Q24186767-488B9D15-664B-4CBC-81DE-AD15D19493D7Q26470649-48272E20-22DE-47E8-A26B-AD1923E7D55BQ26753138-00518741-B9D9-4054-A36A-3AACCB790CD8Q26772119-B46D4493-A60E-4CFD-9DA6-95ABEC5DBF56Q26821898-6A20534C-8C40-4C3A-AF27-B24B362FF007Q26823561-3CC5DD43-5D0D-4F9B-89CE-87A007944AA8Q26824961-217B7344-4659-4234-A119-E5C75FC1577FQ26825944-4ED4263D-2C7C-4520-9B43-718AD615C2B9Q26999313-0C3EAC66-15B0-4A5C-A86A-76F445E00D1DQ27006887-EADD1F52-40D3-420E-9BBA-12FED5647A00Q28070059-8ED1DD31-F1C7-4537-B83F-25720095017EQ28077703-E3DBAA27-4F6F-4473-8483-E7693FE7198DQ28396749-35272F66-D43B-4651-9868-A03D5EED2A1AQ30238816-CA477E42-A952-4667-987D-21580281D7F4Q31081624-7A384D80-1E9B-4C0F-A086-5A9B5F0BAFAFQ33552701-FFFF3FF3-ACB5-4485-88A0-4573E086EA85Q33675229-1BBCE029-C9FA-4021-9154-41870DB0FD09Q33685738-1AAF84AE-5FDA-4528-B0A8-54FC0C75F61AQ33719116-092F6EA8-6BD1-40CA-8CA5-3ECDAE84EEFBQ33723367-A89D8F49-B9E1-459A-A13D-E8E05EC03F40Q33748427-DCF25E8F-828B-42BD-A8C0-DB5C1CABC7AFQ33795662-C40712A6-F8BE-480D-8D4B-2FE1AD5A9804Q33810591-18F46B19-B692-4BBE-AC61-C4301B024AB9Q33947633-AAAB416E-EC71-4CF6-B40A-3187986CD89DQ34105094-6E922FF2-6CCD-4ED6-B000-EDB98FDA3D1DQ34184995-F3D88632-2750-4A64-B883-283D3BF53DAEQ34291076-2A7D5EEB-3A21-46A9-B6E2-C90DB9D9E15FQ34316015-A3654B23-4E3C-4129-845B-B24D5ABDA6F8Q34402444-40381339-2068-43EC-830A-87042DBC1BE7Q34430577-087A437B-B0BD-4CA6-A37E-4D2AF0D574D4Q34798448-19859571-F722-4CAB-B47F-3B67EF689BDDQ35152507-57660E21-272A-48CA-90EF-425CD8CB0B11Q35154329-6E4E075C-FDFA-415F-8EA9-E9CBF7BF6E3CQ35156164-65B4C6CA-2660-4E91-B158-878E21017B84Q35231034-5AE6A681-86BF-4D00-83F8-D9504485D701Q35633471-ACAB2D2F-857A-438B-81CA-F25063204311Q35675286-15738511-6E49-4210-B9E3-EC001B3ACD58Q35782767-8A5705A9-0D9B-430F-A881-7137602FB60BQ35886979-66F5A007-A42C-4B74-AC4A-8149C6892B1BQ36015061-E60351BF-E3EC-4DC5-ACBF-5BEC5FB214EA
P2860
Vaccines for preventing pneumococcal infection in adults
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Vaccines for preventing pneumococcal infection in adults
@ast
Vaccines for preventing pneumococcal infection in adults
@en
Vaccines for preventing pneumococcal infection in adults
@en-gb
Vaccines for preventing pneumococcal infection in adults
@nl
type
label
Vaccines for preventing pneumococcal infection in adults
@ast
Vaccines for preventing pneumococcal infection in adults
@en
Vaccines for preventing pneumococcal infection in adults
@en-gb
Vaccines for preventing pneumococcal infection in adults
@nl
prefLabel
Vaccines for preventing pneumococcal infection in adults
@ast
Vaccines for preventing pneumococcal infection in adults
@en
Vaccines for preventing pneumococcal infection in adults
@en-gb
Vaccines for preventing pneumococcal infection in adults
@nl
P2093
P2860
P3181
P1476
Vaccines for preventing pneumococcal infection in adults
@en
P2093
David Paul Tatham
John Holden
Ross M Andrews
Sarah Moberley
P2860
P3181
P356
10.1002/14651858.CD000422.PUB3
P577
2013-01-31T00:00:00Z